The study, titled ‘Physics of animal health: On the mechanobiology of hoof growth and form’, represents the fruit of a collaboration between researchers in equine medicine, maths, physics and stem cell biology. It was conducted by the School of Veterinary Medicine and Science at University of Nottingham in collaboration with the Waltham Centre for Pet Nutrition and the Royal Veterinary College.
Lead author Dr Cyril Rauch said: "With new scientific inputs from physics, mathematics and biology, this study provides an entirely new paradigm regarding hard growing tissues such as the horse hoof, which can be applied across cattle, sheep and other species, to unify a set of apparently disparate conditions and clarify the roles of physics and/or biology."
Using hooves from horses euthanased for non-research purposes, the study revealed how it is possible for the hoof growth rate to be greater than the potential proliferation rate of epithelial cells. It also explained how the synthesis of the hoof capsule starts from the coronet and that the soft papillae undergo gradual transition through three interpapillary regions into hard keratinised tissue.
Mathematics, physics and cell biology were then used in the study to explain and describe how the dorsal hoof wall can grow in a curved manner rather than the usual straight manner as a result of faster growth from the coronary band at the quarters compared to the toe region.
Evaluation of the feet from live underweight and obese subjects (assessed using Body Condition Scoring) allowed the influence of body weight on the balances of the stresses affecting hoof growth to be evaluated. The results suggest that being proportionally heavier may promote straighter hoof growth and that being too lean may precipitate poor hoof growth and the development of a hoof with a dorsal curved shape.
The study also showed that a high concentration of insulin stimulated equine progenitor keratinocytes (the outermost layer of cells on the hoof wall) to grow in culture. If this also happens chronically within the live animal, it is possible that it could affect the growth stresses within the hoof and so promote a dorsal curved hoof shape.
Co-author Nicola Menzies-Gow said: "These results taken together can explain how the hoof grows and how it is possible for it to develop a dorsal curvature. However, it should be acknowledged that this does not take into account the genetic or metabolic influences on hoof growth nor the role of hoof trimming and shoeing in maintaining a mechanically healthy hoof. It is appreciated that the underlying biology of hoof growth remains an essential factor for hoof pathologies."
Dr Cyril Rauch continued: “Given that the hoof is a weight bearing element it is essential to untangle the biology from the physics in this system; only then can meaningful biological and/or physical causes be prescribed for particular hoof shape. Removing the cause(s) when physically or biologically possible is essential to resolve hoof conditions."
Reference
In case you missed the email last month, Novartis Animal Health has announced the launch of Atopica for Cats (cyclosporine oral solution, 100 mg/ml), a treatment for chronic allergic dermatitis.
This disease, which is apparently one of the most common reasons for pet owners to take cats to the veterinary surgeon2, can be difficult to diagnose and causes itching and associated chewing and licking, skin lesions and loss of hair. Atopica for Cats is the first medication approved in the UK specifically for allergic dermatitis in cats.
Novartis says the new product provides relief from the uncomfortable and recurrent itch/scratch cycle, and the majority of improvements are seen in the first four weeks3-5. The company also says that in clinical trials, 84 per cent of cats diagnosed with allergic dermatitis were considered to be "uncomfortable" at the start of the study5. After six weeks of treatment with Atopica for Cats, 78 per cent of cats were considered "comfortable" with satisfactory levels of grooming3 - a key indicator of a healthy cat. Additionally, Atopica for Cats is proven to significantly reduce unsightly and painful skin lesions and has a proven safety profile.
Anne-Laure Driscoll, Atopica Brand Manager, Novartis Animal Health UK, said: "Veterinarians and pet owners understand the discomfort and frustration of an itchy pet. We are pleased to add Atopica for Cats to our proven family of Atopica products, offering an effective treatment for cats suffering from the extreme discomfort associated with allergic dermatitis."
Developed specifically for domestic felines, Atopica for Cats is an oral solution which Novartis says is easy-to-dose and administer. In studies, approximately one-third of cats took the medicine in their food and two-thirds were dosed directly into the mouth3,4. According to the company, the product offers a unique mode of action that specifically targets immune cells such as the T-lymphocytes involved in the allergic reaction. In this way, Atopica for Cats blocks the production of inflammatory cytokines, molecules that fuel the allergic response, breaking the recurrent itch/scratch cycle.
Dr. Keith Hnilica, DVM, MS, MBA and DACVD, and author of Small Animal Dermatology: A Color Atlas and Therapeutic Guide (3rd ed), said: "Atopica for Cats has the potential to change how our profession treats the itchy cat. For the first time ever, we have a safe, highly effective, approved treatment for cats with allergic dermatitis. And because Atopica for Cats is not a corticosteroid, I can prescribe it for long-term use without worrying about the health risks that can be associated with steroids."
References
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
The Adaptil Diffuser has been renamed the Adaptil Calm Home Diffuser, the Adaptil Collar has been renamed Adaptil Calm On-the-Go Collar, Adaptil Spray is now called Adaptil Transport and Adaptil Tablets are now called Adaptil Express.
The new products are split into three colour-coded groups. In blue packaging, Adaptil Calm Home Diffuser is designed to help dogs stay calm in recurring situations at home, including staying alone, loud noises and visitors. It comes as a 30-day starter kit containing a diffuser and refill, and lasts for 30 days.
Adaptil Calm On-the-go Collar is for use when dogs face fearful situations outdoors. It is available in two collar sizes (small to fit necks up to 37.5cm and large to fit necks up to 62.5cm) and it lasts for four weeks.
Adaptil Transport comes in yellow packaging and is designed to make travel and visits to the vet less stressful. It is available in 60ml and 20ml bottles.
Adaptil Calm Home Diffuser, Adaptil Calm On-the-Go Collar and Adaptil Transport all contain dog appeasing pheremones to help dogs feel calm and relaxed.
The last product in the new range is Adaptil Express, which comes in green packaging. Adaptil Express is an oral supplement which Ceva says provides a fast, calming effect for dogs faced with occasional challenging events such as thunderstorms and fireworks. The non-pheromone tablets, which come in packs of 10 or 40 tablets, combine GABA and amino acids and can be given with or without food.
Abigail King, product manager for Adaptil, said: "80% of pet owners state that their dog gets stressed during challenging situations both inside and outside the home and during specific occasions such as travelling, fireworks and thunderstorms1. Adaptil’s new product range caters for all these eventualities and the eye-catching branding and packaging clearly indicates which product should be used for each challenging occasion to aid owner compliance and help dogs feel calm and relaxed at all times."
For further information, visit www.adaptil.com/uk.
Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.
The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.
According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.
The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.
Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.
Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."
Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.
Denamarin is available for both dogs and cats in an enteric-coated tablet.
Alexander McKinstry and Andrew Rutherford were both charged with writing letters indicating that Rebecca Inman had undertaken an assessment when in fact they had done the assessments themselves, the former without Ms Inman's knowledge, the latter with.
The charges were that all three, who worked at the same practice group in North-West, had been dishonest, misleading and risked undermining procedures designed to promote animal welfare.
At the outset of the hearing, all three admitted the charges against them and the Committee found serious professional misconduct in the case of all admitted charges.
The Committee then considered the sanctions for all three of the respondents.
In the cases against Mr McKinstry and Mr Rutherford, the Committee considered that the conduct was premeditated, that they had an increased position of trust and responsibility as practice directors at the time of the misconduct and that it was a breach of trust for the farm clients.
Additionally, Mr McKinstry had put Dr Inman’s professional reputation in jeopardy by not informing her of his conduct.
In mitigation, the Committee considered that there was no harm or risk of harm to animals, the conduct was not done for personal financial gain, that both had been open and frank in their dealings with the RCVS and had shown insight into their behaviour, and their previous good character and unblemished careers.
Regarding Dr Inman, the aggravating factors were the abuse of her position of trust as a registered mobility scorer and the breach of trust with the farm clients.
In mitigation the Committee considered that it had been an isolated incident involving, from Dr Inman’s point of view, a single telephone call.
It also considered that there was no risk of harm, no personal financial gain, her open and frank admissions in dealings with the RCVS, demonstration of insight, previously unblemished record, and efforts to avoid repeats and remediate past misconduct.
Paul Morris, chairing the Committee and speaking on its behalf, said: “The Committee carefully weighed the demands of the public interest, as well as the previously stated mitigating and aggravating factors and all the particular circumstances before it.
"The Committee concluded that a period of suspension was sufficient and proportionate in this case to meet the need to maintain public confidence in the profession and uphold proper standards.
"It had a sufficient deterrent effect upon others in the profession and was sufficient to mark that the disgraceful conduct was unacceptable.
“The Committee considered all of the factors before it, and decided that given the personal mitigation in this case, as set out above, a period of one month was appropriate and proportionate in all the circumstances."
The full findings of the Disciplinary Committee regarding this case can be found at: www.rcvs.org.uk/disciplinary
Vets4Pets has unveiled its latest national TV advertising campaign, which airs for the first time during Coronation Street on ITV tonight.
The 30-second commercial was shot at five different locations around the UK and features John Davies-Riand MRCVS Vet Partner at Vets4Pets Leeds and Sarah Scott Vet Nurse Partner at Vets4Pets Kettering.
The commercial is running nationally until 28th March and forms part of a national campaign offering owners of elderly pets a discounted £25 senior pet health check with a vet and a half price bag of senior pet food.
Gill Hammond, Head of Brand Marketing said: "It was really important to us when planning this new campaign that we feature our real partners, they are at the end of the day the core of our business and the faces that our clients see when they visit us. The offer itself, focusing on senior pets is testament to our partners' and their teams' commitment to on-going pet health care."
Lee Ashton, founder of Bugler Smith, the agency behind the new ad said: "Working with Vet4Pets on this project has been a really exciting process. Having got under the skin of the brief, and carried out some initial research within Vets4Pets practices nationwide, the overwhelming and consistent theme from everyone we spoke to, was how they have a real passion for pets and making every difference they can.
"This was key to our message, and we felt it was really important to use their best brand ambassadors (their own vets and veterinary nurses) to introduce the brand to the public, to really demonstrate in a straight forward way what makes them different to other vet practices, and we're really pleased with the outcome."
The company says that the effervescent tablet presentation was designed to significantly improve vaccination practices for poultry producers while maintaining reliable virus protection.
Boehringer says this dispensing form reduces the risk of stock solution contamination and, when compared to glass vials, the small blister packs make vaccine management safer for operators, take up less room in the fridge and reduce packaging waste by 90%.
HatchPak IB H120 NeO will be available shortly in packs of 10 tablets of 1000 doses or 10 tablets of 2000 doses.
Callum Blair, Boehringer Ingelheim Avian and Swine Brand Manager, said: "The addition of HatchPak IB H120 NeO to our NeO product portfolio is evidence of our continued investment in the poultry sector."
ISFM points to an editorial published ten years ago in The Lancet (Hypertension: uncontrolled and conquering the world), which presented alarming facts about hypertension in people: the risk of becoming hypertensive during a lifetime exceeds 90% for people in developed countries, with over 1.5 billion adults expected to have hypertension by 2025. It also said: 'screening is not done systematically, and the diagnosis is often made at a late stage when target organ damage has already happened'.
The Society says there are broadly similar concerns in our feline companions. Hypertension is a well-recognised condition in older cats, yet probably remains significantly underdiagnosed. The consequences can be severe, with target organ damage typically affecting the eyes, heart, brain and kidneys. Some damage, such as blindness resulting from complete retinal detachment, is irreversible. Other damage, however, is more amenable to antihypertensive treatment, highlighting the importance of early diagnosis and intervention. However, this presents challenges, particularly as routine blood pressure monitoring is generally performed infrequently in cats. Furthermore, cats are notoriously susceptible to stress in the veterinary clinic, which can lead to 'white coat hypertension' and hamper interpretation of results.
The new ISFM consensus guidelines are published in its Journal of Feline Medicine and Surgery1. The recommendations are those of an expert panel of veterinary clinicians and academics gathered from the UK, Australia, New Zealand, Spain, France and the USA, and cover several key areas. They include: how often to monitor blood pressure for cats of different ages and health status; when antihypertensive therapy is justified based on different systolic blood pressure readings and evidence of target organ damage; and what an investigation of hypertensive cats should include.
Samantha Taylor, a specialist in feline medicine and one of the co-chairs of the guidelines panel, said: "Well-illustrated and easy to read, it is hoped that these guidelines will encourage more widespread monitoring of blood pressure in veterinary clinics to increase the early identification of this treatable condition, and prevent the severe clinical consequences of untreated hypertension."
Accompanying the guidelines, which are endorsed by the American Association of Feline Practitioners, are further resources to assist veterinarians with the diagnosis of hypertension. A blood pressure evaluation form can be downloaded from the supplementary material; in addition, a series of short videos produced by the ISFM on measuring blood pressure in cats is available in various languages at https://www.youtube.com/user/iCatCare/playlists.
Kruuse has announced that it has become the exclusive UK and Ireland distributor for Pulse Veterinary Technologies LLC shockwave systems, including the Versatron, Versatron 4paws and Equitron.
Shockwave therapy, otherwise known as extracorporeal shock wave therapy (ESWT), uses a high-energy sound wave that rapidly increases pressure as it travels through tissue. It is a non-invasive modality used to stimulate healing particularly in ligament, tendon or boney structures.
Andrew Groom, Managing Director, Kruuse UK Ltd said: "This agreement widens the Kruuse equine and small animal capital equipment profile within the UK and Ireland; increasing the range of technologies available to the veterinary practitioner , whilst providing aftercare support of existing shockwave users".
Eric Goorno , Chief Executive Officer, Pulse Veterinary Technologies LLC said: "This exciting partnership will further enhance our presence within the veterinary industry and allow Kruuse UK to bring leading edge technology to its customers, building upon its strong relationships within veterinary practices".
Outcome of temporary tracheostomy tube-placement following surgery for brachycephalic obstructive airway syndrome in 42 dogs1 was undertaken at Dick White Referrals, UK. A retrospective case series of dogs that had a temporary tracheostomy tube placed in the post-operative period following surgery for BOAS was obtained from the referral hospital.
Of the 42 dogs, 11 had a tracheotomy tube placed electively and 31 had one placed as an emergency. The overall postoperative complication rate in the study was 95%. The minor complication rate – defined as resulting in no observable compromise of the clinical status and/or self-limiting, such as a cough - was 71%. The major complication rate – defined as resulting in discernible harm to the patient, such as cyanosis and dyspnoea - was 83%. 41/42 dogs were classified as having successful tracheostomy tube management.
Marius Stordalen, lead author of the paper said: "Contrary to what had been previously thought, this manuscript shows that in an appropriate clinical setting, temporary tracheostomy tube placement following multi-level airway surgery for brachycephalic obstructive airway syndrome carries a good prognosis for the majority of patients."
Nick Jeffery, editor of JSAP added: "Whilst overall mortality rate was low following placement of a tracheostomy tube in the postoperative period, there was a high overall complication rate. This finding demonstrates the need for continuous monitoring and intensive care for patients following placement of tracheostomy tube.”
The full article can be found in the May issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13127
The RCVS Disciplinary Committee has dismissed a case against a veterinary surgeon said to have been dishonest in claims made against insurance following a dog's veterinary treatment.
At the end of the four-day hearing, the Committee found Sheena Brimelow, formerly employed by Kinver Veterinary Practice in Kinver, Stourbridge, not guilty of charges relating to seven insurance claims submitted between 1 January 2008 and 1 October 2009. These related to her parent's dog, a Cairn terrier, which she had treated at her then employer's practice. Ms Brimelow admitted that she had submitted invoices with her claims showing the retail prices for several items, when she had paid the practice only the cost prices. She said that she had deleted records from the practice computer showing the retail prices so that the ingoings and outgoings in the practice finances were accurate.
The Committee considered whether Ms Brimelow had either behaved dishonestly or, in the alternative, ought to have known not to have included the sums she did in the insurance claims forms. The Committee found that Ms Brimelow was an honest and reliable witness. She had explained openly what she had done, entirely consistently, from the first time the allegations had been put to her by the practice owner. It noted that an insurance company representative also considered her actions to be "a genuine misunderstanding," although subsequently a complaint was made by the insurance company to the College about Ms Brimelow's actions. The Committee found there were no clear guidelines in the practice as to how staff insurance claims should be handled. It also felt that, as a result of the insurer's communications failures, it was not difficult to believe that Ms Brimelow was unaware of how claims concerning the insured pets of veterinary practice staff members were expected to be handled.
From the evidence presented in the hearing, the Committee calculated that Ms Brimelow had benefited by only £90.50. The Committee noted that she had offered to repay any monies to her employer or the insurer, and that the insurer's loss adjusters had thought this was a matter for Ms Brimelow and her employer. The College had also referred the matter to the police, who said it was not in the public interest to proceed with the matter, a decision they based on the low value of the loss and Ms Brimelow's offer to pay back the money.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "The Committee notes the reasons given by the police for undertaking no criminal investigation in this case, and agrees with that analysis. The Committee must apply the same standard of proof as would have been applied in a criminal case. In all the circumstances, the Committee is far short of being satisfied so that it is sure that Ms Brimelow acted dishonestly in this case."
"The Committee considers that [Ms Brimelow] was naïve and misguided in handling the insurance claims in the way that she did," he continued. "However, the Committee considers there was a lack of proper guidance within the practice as to how staff insurance claims should be handled. In these circumstances the Committee is not sure that the College has proved that the Respondent ought to have known that she should not have included sums on the claims form, which did not represent the costs that she had incurred."
Both elements of the charge were accordingly dismissed.
THE Society of Practising Veterinary Surgeons (SPVS) has published its annual Salary Survey, which provides a guide to what full time assistants are now earning.
The survey, which asked the society's members and anyone on the RCVS Register qualified for under three years to provide details about employees' salary levels, uniquely provides a breakdown of what full-time assistants are earning.
Respondents were asked to provide details of their basic salaries together with any benefits in kind such as rental accommodation, access to a car and CPD allowances, and total remuneration packages were calculated.
The survey, which is distributed along with the annual Fees Survey to SPVS members as a key benefit of membership, provides a breakdown of minimum, average and maximum salaries over categories ranging from location to the number of years qualified.
For the second year, student loan levels are featured, which, worryingly, highlights the increasing number of students graduating with large value loans.
Richard Hillman, SPVS President, said: "I very much welcome the publication of this important annual survey, which comes at a time when vet salaries and the fees we charge are under fire. It is interesting to note that the recent ‘league table' which effectively labeled us the ‘fat cats' among small businesses was based on the minority of corporate practices."
He added: "Our survey provides a very valuable base for employers to develop a transparent pay scheme and for employees to negotiate. It is particularly useful with new legislation on greater transparency of pay scales in businesses and the outlawing of salary ‘secrecy clauses' together with the Government's push for equality in male/female pay awards."
The SPVS annual Fees Survey, which provides a breakdown of fees charged across the small animal, cattle and equine sectors, will be published in September.
SPVS is run by practitioners for practitioners and if you'd like further information on the courses and membership benefits that SPVS offers, please contact the secretariat on 01926 410454 or visit the web site at www.spvs.org.uk
Only about a third of vets and a quarter of nurses believe in a God, according to a poll carried out amongst the members of www.vetsurgeon.org and www.vetnurse.co.uk
The poll offered four possible responses to the question: Does God exist? The results from 124 vets were:
Interestingly, the results were more polarised amongst vets than nurses. Fewer nurses described themselves as believers (24.4%) or atheists (39.5%), with many more describing themselves as agnostic (33.6%).
The VetSurgeon poll suggests that vets and nurses are less likely to believe in God than the general population. In 2004, a survey commissioned by the BBC found that 56% of Britons believed in God, and in 2005 a survey by the European Commission found that 38% of Britons believed in God.
When it comes to religion, it seems that vets have more in common with today's teenagers. A survey announced by Penguin books yesterday to mark the publication of 'Killing God' found that only 34% of those aged 13 to 18 believe in God.
Another survey in 2008 found that only 3.3% of Royal Society fellows believed in God, causing researchers to conclude that people with a higher IQ are less likely to have faith, a finding which tallies with a previous Gallup survey which showed that American postgraduate degree holders were less likely to believe in God than those who had been through high school only.
So, hard to tell whether the lack of belief in God amongst vets is due to superior intellect, or developmental problems!
Either way, good to see that the God complex is alive and well in the veterinary profession: 4.8% voted for the fourth option in the VetSurgeon poll, which was: "Don't be so silly, I AM God"
Revozyn RTU, which contains 400 mg/ml Penethamate hydriodide, is the first ready-to-use injectable narrow spectrum Penethamate on the UK market. It can also be used to treat relapses of old infections.
Dechra says that the intramuscular injection works by diffusing through the blood vessels and accumulating in the udder tissue and milk, treating the whole udder effectively. Apparently the new formulation also features an ion trapping mechanism that results in high Benzylpenicillin concentration in milk and udder tissue.
Revozyn RTU comes in a 50ml multi dose vial. It has a 28-day shelf life after first use and has withdrawal periods of four days for milk and 10 days for meat and offal.
Dechra Brand Manager Emma Jennings said: "The treatment and control of mastitis is one of the largest costs to any dairy farmer. It affects productivity and cow welfare and we are delighted to be able to introduce this revolutionary product.
"Revozyn RTU can change the way that clinical and subclinical mastitis in dairy cattle is treated. Its narrow spectrum of activity means that the risk of antibiotic resistance is reduced and there is no need for additional animal handling, thereby saving time and protecting user safety.
“The flexible dosing of Revozyn RTU and 28-day shelf life also make it a cost effective option for farmers".
For more information, visit www.dechra.co.uk.
Zoetis has launched UlcerGold (omeprazole) for the treatment - and prevention of recurrence - of gastric ulcers in horses and foals, presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg.
Equine Gastric Ulceration Syndrome (EGUS) is a serious and common condition affecting horses and foals.2,3 Approximately 90% of racehorses, 60% of performance horses, 37% of leisure horses and 50% of foals have been shown to be affected.2,4,5 The condition is associated with injury to the mucosa of the oesophagus, stomach and duodenum, with prolonged exposure to gastric acid thought to be the primary cause.2,3 Risk factors include stress, intense exercise, a high-grain diet, intermittent feeding and illness.2,3 EGUS can have a profound impact on a horse's condition and performance and can ultimately be life threatening, especially in foals.3,5 It is a challenging condition to diagnose as the clinical signs are often vague and not always present.3 Gastroscopy is the only method currently available for a definitive diagnosis and treatment is usually based on acid suppressive therapy to allow ulcer healing.2
UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.1 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.1,2 One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Zoetis says UlcerGold is supported by a comprehensive gastroscope training programme, pricing model, client support and communications plan to ensure that it is a strong asset to veterinary businesses.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health."
Leishmaniosis is caused by the parasite Leishmania infantum, which is endemic in some areas of Europe, but not in the UK. The patient in this case had not travelled outside the UK.
In endemic areas, the infection is carried by female sand-flies and spread through sand-fly bites. Transmission has also been reported via dog bites from an infected dog and infected blood transfusions, although the RVC says these routes have not been reported in the UK before.
Dogs with Leishmaniosis display a range of signs that can take months to years to develop after initial infection. Typical signs include:
Weight loss
Lack of energy or enthusiasm
Increased thirst and increased urination
Changes to the skin (particularly around the eyes, ears and feet)
Vomiting or diarrhoea
Lameness due to joint pain
Sudden nose bleeds
Soreness around the eyes
Treatment is available for dogs with leishmaniosis, but infection is difficult to clear and long-term medication is therefore frequently needed. Leishmaniosis can be zoonotic - meaning it can be passed to people in rare situations.
Apparently there is another leishmaniosis case reported in the Veterinary Record this week, this time where the dog was suspected of contracting the disease via sand-flies unintentionally brought back in its owners' luggage following a trip to Spain.
Myles McKenna said: "It is important to take note of this first reported case of likely dog-to-dog transmission of Leishmania infantum in the UK. Historically we had considered this to be a condition affecting dogs with a travel history to areas where Leishmania infantum is endemic. Dog-to-dog transmission in non-endemic areas has previously been reported, for example in the USA, but this case serves as a reminder to UK veterinary surgeons that we must be vigilant for conditions such as Leishmania in non-travelled dogs and that alternative transmission mechanisms do exist."
The Vet Record has published four recommendations to protect dogs and humans in the UK from leishmaniosis.
Photo: Bone marrow cytology showing macrophages with numerous intracellular organisms consistent with Leishmania species amastigotes. Credit Charalampos Attipa
Miss Padron Vega faced four charges. The first and second alleged that in February 2016, for the purposes of an application to the Food Standards Agency for a Certificate of Competence under the Welfare of Animals at the Time of Killing Regulations 2015, she backdated two separate veterinary witness certificates to 7 December 2015. The third charge alleged that her acts of backdating were misleading, dishonest and in breach of the RCVS Principles of Certification.
The fourth charge against Miss Padron Vega was that, between September 2015 and February 2016, she failed to fulfil her duties as an Official Veterinarian in respect of: failing to prepare herself for the implementation of the Welfare of Animals at the Time of Killing Regulations 2015; failing to have regard to the information provided to her by her employers about the regulations and their implementation; failing to take any steps to ensure that the two individuals for whom she had given veterinary certification were licensed to perform slaughter in accordance with the regulations; and failing to identify that two individuals were not licensed to slaughter in accordance with the regulations.
The Committee heard that the Welfare at the Time of Killing Regulations were introduced on 5 November 2015 which placed the responsibility on slaughtering operations not to permit animal welfare abuses and required certification by a veterinary witness regarding compliance.
The new regulations required existing slaughter licence holders to apply for a Certificate of Competence before midnight on 8 December 2015 or they would not be permitted to continue operating even with experienced operatives.
During the hearing, Ms Padron Vega admitted charges 1 and 2, admitted that she had been in breach of the Principles of Certification and admitted the fourth charge against her.
However, she denied she had backdated the certificates in a misleading or dishonest way, maintaining that she had done so by mistake.
In considering the facts of the case, however, the Committee rejected this argument and, taking into account that she had been responsible for veterinary certifications in the UK since 2001, found that her conduct was knowingly misleading and dishonest.
The Committee then went on to consider whether the charges she admitted and the charges found against her constituted serious professional misconduct, both individually and cumulatively.
The Committee found that all the charges amounted to serious professional misconduct.
In relation to charge 4 in particular Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The Committee has found that the respondent failed to read even those emails which her employer sent to her which were marked ‘urgent’ or ‘OV importance high’. She must have known that her employers were directing attention to some new statutory scheme for she was provided with PowerPoint slides in that regard which she could read at any time of her convenience. The Committee has been driven to the conclusion that the respondent did not even bother to read those slides for, had she done so, she would have known that she needed to apprise herself of the requirements of the impending new statutory scheme.
"The respondent’s failings in this regard are little short of extraordinary, especially given her obligations as Lead OV for FAI Farms. The total abdication of her responsibility to understand the requirements of the Regulations governing the slaughterhouse operations constitutes, in the judgement of this Committee disgraceful conduct in a professional respect."
The Committee then went on to consider the aggravating and mitigating factors in the case. In terms of aggravating features the Committee noted a lack of insight into the gravity of her conduct, that her conduct undermined in the most serious way public confidence in veterinary certification, and that there were animal welfare implications on her conduct as a number of chickens had to be removed from the slaughterhouse and alternative arrangements made because an auditor from the Food Standards Agency found that it was not compliant.
In mitigation the Committee considered that, despite the potential risk of harm, there was no actual harm occasioned to animals, that Miss Padron Vega has had a long and otherwise unblemished career and no previous issues with the RCVS and that she had admitted some of the charges against her.
Stuart Drummond added: "Ultimately, the Committee was driven to the conclusion that the public’s desire to see the implementation of the highest certification standards in relation to activities which impact on animal welfare and public health, and which did not occur on 3 February 2016, must outweigh this particular veterinary surgeon’s desire and need to continue in practice. This is not a conclusion which the Committee has arrived at lightly. On the contrary, it has reached this decision because it has been driven to the conclusion that it would be failing in its public duty to protect the wider public interest in the maintenance of standards of honesty and right conduct in a member of the profession.
"It is, therefore, the conclusion and decision of this Committee that the only proper sanction that can be imposed in this case is that the respondent’s name should be removed from the Register and it directs the Registrar accordingly."
Miss Padron Vega has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
Ms Mulvey faced a total of nine charges against her:
Ms Mulvey did not respond to the charges, was not present at the hearing and was not represented.
She told the College that she couldn't attend for health reasons, but did not then provide any medical evidence and did not apply for a remote hearing, which was offered.
She had appeared before the Disciplinary Committee twice previously, facing a number of similar charges.
In 2016/2017, Ms Mulvey admitted all charges she was faced with and was found guilty of disgraceful conduct in a professional respect.
The Committee then decided to postpone the sanction for a period of one year.
In 2019, Ms Mulvey appeared before the Committee for the resumed sanction hearing and faced further new charges relating to failures to provide clinical history, failing to communicate with clients, failing to respond to requests for information from the College concerning complaints made against her, continuing professional development and indemnity insurance.
Ms Mulvey admitted the new charges and that she was guilty of disgraceful conduct in a professional respect, for which she was struck off for six months.
Taking into account the fact that this was not Ms Mulvey’s first time before the Committee, as well as new accompanying evidence, the Committee considered the facts of each subsection of each charge individually.
The Committee found all charges proved, apart from one subsection of charge 1.
The Committee then went on to decide if Ms Mulvey was guilty of disgraceful conduct in a professional respect, noting that it was entitled to consider the facts on a cumulative basis.
In other words, whilst any one charge may not fall far below the relevant standard expected of a veterinary surgeon on a standalone basis, it may when considered in conjunction with other failings that have been found proved.
The Committee found a number of aggravating factors in the case, including actual injury to animals (including death and amputation), dishonesty, breach of trust, sustained behaviour, disregard of the role of the RCVS, lack of insight by the defendant and previous adverse findings.
There were no mitigating factors.
The Committee then went on to decide upon a sanction.
Paul Morris, chairing the Committee and speaking on its behalf, said: “The Committee found that Dr Mulvey has demonstrated a wilful disregard for the role of her regulator and the systems that regulate the profession which are designed to ensure animal welfare.
"She has failed to learn from, or respond to in any meaningful way, her previous appearances before her regulator and advice given.
"The instant charges found proved dated back to shortly after the earlier suspension had elapsed.
"The Committee further noted that, if a period of suspension were to be imposed, at the end of the suspension Dr Mulvey would be entitled to resume practice without any preconditions.
“This is a case involving serious malpractice.
"It was sustained over a period of time.
"It followed previous adverse findings for almost identical failures.
"From as long ago as 2013, Dr Mulvey was given ample opportunity and support to remedy the deficiencies in her practice, which she squandered.
"Dr Mulvey’s conduct had very serious consequences for animal welfare.
"She continued, and continues, to display a wilful disregard for her responsibilities as a veterinary surgeon under the Code of Professional Conduct.
"Dr Mulvey’s conduct was a gross departure from the conduct expected of a veterinary surgeon.
“Dr Mulvey’s disgraceful conduct is so serious that removal from the Register is the only means of protecting animals and the wider public interest which includes protection of the public, the maintenance of public confidence in the profession, and the upholding of standards.”
Dr Mulvey has 28 days from being notified of her removal from the Register to lodge an appeal with the Privy Council.
https://www.rcvs.org.uk/concerns/disciplinary-hearings
The research, conducted with the Blue Cross, analysed data from over 2,000 UK dog owners and identified perceptual barriers to welfare reforms.
The study revealed that many owners normalise health issues associated with brachycephalic conformations, including breathing difficulties, eye conditions, and skin infections.
One in seven owners of extreme brachycephalic dogs said that 'nothing' could dissuade them from owning these breeds, particularly those with a strong preference for flat faces and those that did not believe brachycephaly reduced a dog’s lifespan.
Owners of extreme brachycephalic dogs, such as French Bulldogs, found the perceived trait of 'laziness' to be highly desirable, despite the fact that an inability to exercise is often a symptom of brachycephalic obstructive airway syndrome (BOAS).
The researchers propose a series of interventions to overcome these barriers and make campaigning more effective, including:
Dr. Rowena Packer, lead researcher, said: "Future strategies to tackle the brachycephalic crisis must do more than presenting purely health-based data in generic public locations, and instead, positively offering possible alternate breeds, myth-busting false beliefs and leveraging human stories of brachycephalic owners to have greater impact.
"Additionally, specifically targeting these messages on social media and puppy-selling platforms may increase their efficacy.”
Remote consultations and prescribing have been the subject of much debate in the profession of late. A motion to conduct a trial of prescribing without a physical examination was considered by the RCVS Council in November, when a large number of serious concerns were raised.
However, none of those concerns related to the provision of remote consulting services for existing clients with animals who are already under the care of the veterinary surgeon. That's where systems like this could add real value to the service offered by veterinary practices.
George Kyriacou, Director at VVG said: "Telemedicine is happening, and it’s happening in a big way. Virtual consultations are becoming more and more popular with pet owners who are not really sure if they need to see a vet and would simply like some reassurance.
"An option to have a qualified vet in your pocket at anytime of the day is attractive. However, the option to have a convenient consultation with your own trusted vet is the holy grail."
The system allows those practices who wish to charge for online consults to take payment online. Some, however, offer free consultations, in particular post-op, because it saves everyone time.
VVG points out that the system can also be used to deliver nursing consultations, too.
Simon Power, Commercial Manager at Vets One referrals in Crimplesham, Norfolk said: "Since adopting the system we have had a number of post-op and medication reviews virtually; it not only saves us a consulting room but also allows our clients to have the expert advice our team provide from the comfort of their own home."
VVG costs £249 to set up, plus from £59 per month thereafter, per practice.
For more information, contact George Kyriacou at George@thevvg.com or call 01842558022.
The new practice was created by refurbishing the premises of what was a purpose-built human hospital, turning it into a referral clinic with two operating theatres, separate accommodation and waiting rooms for cats and dogs, offices and a seminar room.
Funding for the refurbishment came from NatWest, with further funds for things like digital radiography and a CT scanner coming from Lombard Asset Finance.
Martin said: "We decided to open East of England Veterinary Specialists to offer a more personal, yet professional service for pet owners in the local community. Thanks to the funding from NatWest and Lombard, we have been able to create a well-equipped surgery where we can offer the highest level of veterinary orthopaedic expertise.
"We have enjoyed welcoming our first customers over the past month and look forward to continuing to establish ourselves as an expert orthopaedic veterinary clinic, where 100% of referred cases will be managed by a Recognised Specialist."
For more information, visit: https://eoevets.com or telephone 01223 795023
Photo: L-R Karl Simper, relationship manager at NatWest, Martin Owen, co- founder of East of England Veterinary Specialists, Mat Parkhouse relationship manager at NatWest and Mark Bush, co- founder of East of England Veterinary Specialists.
Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.
Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.
"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.
Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.
"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."
Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.
177 delegates took part in the survey, which found that even the most commonly used digital tool, namely automated reminders, are not being used by more than a third of all practices.
Less than 60% are using digital records.
Less than half are using online booking, which Provet says can significantly improve the customer experience.
Less than 20% have implemented integrated payments or telemedicine or pet owner apps.
The survey also found that 42% are still using old server technology, rather than cloud-based solutions (28%).
The company has produced a guide to what you should look for in a practice management system, including pros and cons of cloud vs. server-based solutions and digital tools that can improve service level whilst saving time, which you can download here.
Fiproclear Combo, which contains fipronil and S-methoprene, is licensed for use on cats and dogs and can also be used to treat and prevent fleas and ticks on ferrets.
Norbrook says the new product provides effective protection from new flea infestations for up to eight weeks on dogs and four weeks on cats, while protecting against certain ticks for up to four weeks on dogs, and two weeks on cats.
Monica Whistler, Norbrook Marketing Product Manager, said: "With its triple-action approach, Fiproclear Combo kills adult fleas, ticks and biting lice. The addition of S-methoprene to the already-trusted ingredient fipronil, breaks the flea life cycle in the home by ensuring that any eggs laid by the fleas, which have come into contact with the product are infertile, and by preventing development of flea larvae within a pet’s surroundings.
"Adult fleas on pets are killed within 24 hours whilst newly arrived ticks are killed within 48 hours of attachment – before the main risk period of disease transfer. Ticks rank second only to mosquitoes as insects that spread infectious diseases to both pets and people1; the most common of which is Lyme disease."
Norbrook highlights research which showed almost a third of cats suffered from ectoparasites2, while around one in every three dogs are affected by ticks3, and that many traditional treatments do not help break the flea life cycle in the home.
Monica added: "Typically, by the time an owner notices a flea problem, an infestation has already been present for up to two months. At that point the visible adult fleas on the pet are only part of the problem, with 95% of the parasites already living in the home itself as eggs, larvae and pupae."